Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Phase 1/2
18–65
2 sites in KS, MO
What this study is about
This Phase 1/Phase 2 study is testing Bendamustine in people with multiple sclerosis. The primary outcome being measured is To assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive Multiple Sclerosis.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bendamustine
Primary: To assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive Multiple Sclerosis.
Secondary: To evaluate disease response, as measured by the Neurostatus Expanded Disability Status Scale (EDSS), To evaluate the effects of TRX319 on disease progression/reactivation by gadolinium-enhancing MRI
Neurology